b. Monoclonal antibody that blocks the tissue factor pathway inhibitor (TFPI) c. Monoclonal antibody that inhibits anti-thrombin III by a linked small interference RNA d. A bispecific monoclonal antibody binding activated factor IX and factor X 4. Vaccinations given for children during the first 75 days of factor VII administration have the higher risk of inhibitor development in children with severe hemophilia A. a.True b. False
3. Patient XY, who had severe hemophilia A and had recently n=been hospitalized for a bleeding episode in his knee, had a follow-up appointment. The existence of a high-titer factor VIII inhibitory antibody measuring 13 Bethesda units (BU) hampered his hospitalization, necessitating the administration of recombinant factor VIIA to control his bleeding.
The possibility of initiating immunological tolerance induction (ITI) to eradicate his inhibitor is being examined as a way to best control future bleeding episodes. The patient inquires if there are any newer medicines on the horizon for hemophilia A bleeding prevention. Those who were given weekly emicizumab prophylaxis has a lower rate of annualized bleeding episodes than those who are not.
What is the mechanism of action of emicizumab?
a. Recombinant fusion protein that binds activated factor IX and factor X
b. Monoclonal antibody that blocks the tissue factor pathway inhibitor (TFPI)
c. Monoclonal antibody that inhibits anti-thrombin III by a linked small interference RNA
d. A bispecific monoclonal antibody binding activated factor IX and factor X
4. Vaccinations given for children during the first 75 days of factor VII administration have the higher risk of inhibitor development in children with severe hemophilia A.
a.True
b. False
Step by step
Solved in 3 steps
